Previously, we generated AAV‐D7, a recombinant muscle‐tropic adeno‐associated virus (AAV) serotype 9 vector carrying the human DOK7 gene tagged with EGFP under the control of the cytomegalovirus promoter, and demonstrated that therapeutic administration of AAV‐D7 enlarges NMJs and enhances motor activity and life span in DOK7 myasthenia model mice (Arimura et al, 2014). Here, DOK7 is linked to Fatigable weakness.